Lupin Ltd. News and Updates

Name: Latest research reports of Lupin Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 1
Author: Geojit BNP Paribas

Keep track of all breaking news on Lupin Ltd. from all sources in a single place.

Load latest

Lupin Ltd.

24 Aug 2020

2004.40

-2.49%

Lupin shars slips 2% after Investec retains 'sell' but raises target

Moneycontrol

Investec raised target on lupin to Rs 815 from Rs 665 per share.

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

21 Aug 2020, 06:04PM

2004.40

-2.49%

Lupin recalls around 561,000 pouches of birth control pills in US market

Business Standard

Drug major Lupin is recalling 5,60,922 pouches of a birth control product in the US, as per the US Food and Drug Administration (USFDA)

Lupin Ltd. is trading above its 150 day SMA of 1980.4

Lupin Ltd.

14 Aug 2020

2004.40

-2.49%

Lupin trades above Rs 1,000 for the first time since Nov 2017

Economic Times

The pharma major last week reported a 64.72 per cent decline in its consolidated net profit to Rs 106.90 crore for the quarter to June 2020, hit by the Covid-19 pandemic.

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

13 Aug 2020

2004.40

-2.49%

Lupin appoints K B S Anand, Punita Kumar Sinha as independent directors

Business Standard

Drug firm Lupin on Wednesday announced the appointment of K B S Anand and Punita Kumar-Sinha as independent directors. Anand most recently served as managing director and chief executive officer at Asian Paints. He currently serves as an independent director on the boards of Marico, Tata Chemicals and Borosil, Lupin said in a filing to BSE. Punita Kumar-Sinha brings significant governance and investment experience across India and North America. She founded Pacific Paradigm Advisors, an independent investment advisory and management firm, and was formerly a senior managing director at Blackstone, it added. She serves as an independent director for several companies, including Infosys, JSW Steel, Blackstone Embassy REIT and Rallis, Lupin said. "We are delighted to welcome Mr K B S Anand and Dr Punita Kumar-Sinha to our board. With their long and illustrious careers, they bring decades of experience in key areas such as innovation, strategy, capital markets and financial expertise

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

12 Aug 2020

2004.40

-2.49%

Buy Lupin; target of Rs 979 KRChoksey

Moneycontrol

KRChoksey is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 979 in its research report dated August 11, 2020.

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

12 Aug 2020

2004.40

-2.49%

LUPIN LIMITED

Sell: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Limited is a multi-national pharmaceutical company based in Mumbai. The company specializes in branded and generic formulations, API's and advanced drug delivery systems in the area of biotechnology. The...

Lupin Ltd. is trading below its 200 day SMA of 2025.5

Lupin Ltd.

11 Aug 2020

2004.40

-2.49%

Buy Lupin; target of Rs 1015: Motilal Oswal

Moneycontrol

Motilal Oswal is bullish on Lupin recommended buy rating on the stock with a target price of Rs 1015 in its research report dated August 08, 2020.

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

11 Aug 2020

2004.40

-2.49%

Lupin pharma launches generic asthma treatment drug in US market

Business Standard

Drug firm Lupin on Tuesday said it has launched generic Zileuton extended-release tablets - used for the treatment of asthma - in the US market. The product is a generic version of Chiesi USA Inc's Zyflo CR extended-release tablets in the same strength, it added. The company has launched Zileuton extended-release tablets in the strength of 600 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a BSE filing. According to IQVIA MAT June 2020 data, Zileuton extended-release tablets had an annual sales of approximately USD 40 million in the US, Lupinsaid. The tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older, it added. Shares of Lupin Ltd closed at Rs957.95per scrip on the BSE, up 0.01 per cent from its previous close.

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

10 Aug 2020

2004.40

-2.49%

Lupin first company to shift manufacturing of some drugs from India to US after Trump's Buy American' order

Moneycontrol

CEO Vinita Gupta does not name the drugs. Analysts say move will not have much effect on Indian pharma sector. Gupta says US business was down 26 percent in Q1FY21 Q-o-Q. Efforts under way to bring Metformin back into the market within Q2FY21.

Lupin Ltd. is trading below its 200 day SMA of 2025.5

Lupin Consolidated June 2020 Net Sales at Rs 3,527.86 crore, down 20.15% Y-o-Y

Moneycontrol | 10 Aug 2020 2 more

Lupin Ltd.

10 Aug 2020

2004.40

-2.49%

Lupin: Execution for US portfolio a key monitorable

Moneycontrol

Lupin's guidance for the portfolio rollout in the US market is encouraging. New launches and an improving market share in Levothyroxine are expected to help tide over structural pricing erosion in the near to medium term

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Is Lupin Ltd. worth buying?

923 Votes:

Buy 72.81%

Sell 17.44%

Hold 9.75%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf